As expected, immunohistochemical evaluation confirms the duality of the disease, with expression of specific markers both of thyroid (thyroglobulin, TTF1, calcitonin) and carcinoid (chromogranin A, synaptophysin, NSE and CD56). This evidence concerns the gene ENO2 and carcinoid tumor.